THANK YOU FOR SUBSCRIBING
A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Pharma Tech Outlook Advisory Board.


Lactobacillus gasseri as Next Generation Probiotics
Lactobacillus gasseri, a probiotic known for its beneficial effects on gut health, has been shown to play a critical role in maintaining a balanced microbiome and supporting immune function.
"In previous projects we have evaluated the probiotic activity of L. gasseri based on the availability of genome sequence and species-specific adaptability to human mucosa. L. gasseri obtains various health benefits through its antibacterial activity, bacteriocin production, and immune regulation of the innate and adaptive systems in humans." -According to a scientist at Creative Biolabs.
Lactobacillus plantarum for Therapeutic Applications
Creative Biolabs also specializes in exploiting Lactobacillus plantarum (L. plantarum), a versatile probiotic having the ability to endure in various environments and its robust probiotic properties, for therapeutic applications. Their solutions focus on the potential of L. plantarum to support digestive health, enhance immune responses, and prevent infections.
"We've collected several L. plantarum products, like powder, cells, and bacteria, to meet diverse research needs." The scientist elaborated.
Advancing Bifidobacterium longum Research
Bifidobacterium longum (B. longum) is another key area of research known for maintaining gut health, supporting digestion, and modulating the immune system. Creative Biolabs assists in the exploration of B. longum's as therapies, particularly in the context of gastrointestinal disorders and immune-related conditions, especially cancer, since B. longum selectively locates and proliferates in solid tumors after systemic application, thus making it optimal for tumor-specific gene delivery and enzyme prodrug therapy.
Innovative Enterococcus faecalis as Therapeutic Candidates
Enterococcus faecalis (E. faecalis), often associated with infections like inflammatory bowel disease, has promising therapeutic applications that Creative Biolabs is keen to explore through the most efficient E. faecalis-based NGP discovery approach.
"We have developed a wide range of NGPs promising for targeted therapy for gut diseases, and our list is growing. But simply identifying new ones is far from enough. We encourage that future probiotic formulations should include sources of isolation, taking into account genetic and phenotypic characteristics, for use in different body parts." The scientist concluded.